A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
SELLAS Life Sciences Group, Inc. (SLS) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-06-30, net income was -32.5m $. Incorporated in the United States.
This summary is compiled automatically from SEC filings and exchange data.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
SELLAS Life Sciences Group, Inc. (SLS) is a company in the Health care sector; its shares trade on Nasdaq.
The price of SELLAS Life Sciences Group, Inc. (SLS) on November 19, 2026 is $14.86, −17.21% on the day. Over 52 weeks the stock traded between $1.39 and $16.54; the price now sits 89% of the way up that range. Over the past year the price changed by +834.59%. Market capitalisation is $2.05 billion, rank 71 among 379 stocks of the same industry with a known capitalisation.
SELLAS Life Sciences Group, Inc. trades on Nasdaq under the ticker SLS. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks SLS has traded between $1.39 and $16.54. As of 19 November 2026 the price stood 88.91% of the way from the 52-week low to the high.
Over one year SLS shares rose 332.45%; over six months they fell 15.17%. Volatility over 90 days is 96.46%. Dividends are not included: this is price change only, as of 19 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to book is 14.9, above the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
SLS has a return on equity of −23.58%, above the sector median of −40.58%. Return on assets is −22.33%, above the sector median of −30.08%.